BerGenBio ASA (FRA:7BG0)
€ 0.708 0.009 (1.29%) Market Cap: 28.14 Mil Enterprise Value: 13.42 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 58/100

Q1 2024 Bergenbio ASA Earnings Call Transcript

May 29, 2024 / 08:00AM GMT
Release Date Price: €1.11 (-1.77%)
Martin Olin
Bergenbio ASA - Chief Executive Officer

Good morning. My name is Martin Olin, and welcome to the quarterly report for the first quarter of 2024 for Bergenbio. I'll just remind the audience about the formalities.

So the highlights of the first quarter, I would characterize it as being continuing on the plan with our focused strategy within frontline non-small cell lung cancer for STK11-mutated patients. And we are very encouraged to have received the recommendation or the decision by the data safety monitoring board from the Phase 1b study to continue in the expansion -- in the additional cohorts but also the opening of the Phase 2a part of the study, which is specifically for STK11-mutated non-small cell lung cancer patients in frontline therapy.

I'm also very pleased to follow up on the announcement we had yesterday, which is that, given the fact that bemcentinib, in our mind, is one of the leading selective AXL inhibitors in the clinic, has been selected to be part of a study run by the university hospital at San Antonio by Dr. Taverna, in combination with pacritinib, a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot